What should you pay attention to when taking Sunitinib (Sutent)?
Before taking sunitinib (Sunitinib), patients need to understand its indications, mechanism of action and potential risks. Sunitinib is an oral multi-target tyrosine kinase inhibitor mainly used to treat renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. Before starting treatment, doctors usually evaluate the patient's heart function, liver and kidney function, and blood indicators to ensure that the patient can tolerate the drug and develop an individualized treatment plan.
During the medication period, patients should pay attention to regular medication and course management. Sunitinib generally adopts a cyclic medication schedule, such as "44weeks on medication+2weeks off" to balance efficacy and toxicity. During the medication process, you should avoid changing the dose at will or stopping the medication without authorization. At the same time, pay attention to recording the occurrence time and degree of adverse reactions to provide a reference for doctors to adjust the dose.

Common adverse reactions of sunitinib include hypertension, fatigue, oral ulcers, hand-foot syndrome, and hematological abnormalities. Patients should regularly monitor blood pressure, blood routine, and liver and kidney function while taking the medication. If any obvious abnormality occurs, the doctor should be notified in time so that dosage adjustments can be made or corresponding intervention measures can be taken. For skin reactions such as hand-foot syndrome, symptoms can be relieved with topical care and pharmacological intervention.
In addition, patients need to pay attention to lifestyle and concomitant medications during medication. Avoid concurrent use of drugs that have significant drug interactions with sunitinib, such as strong CYP3A4 inhibitors or inducers. Patients should maintain healthy living habits, such as a reasonable diet, moderate exercise and regular work and rest, and have regular follow-up visits to ensure maximum drug efficacy and reduce potential risks.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)